Videos

The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.

Jon Mahrt discusses strategies for improving patient access to medications through affordability initiatives and utilization management of high-cost drugs.

The Mental Health First Aid training can bring awareness in pharmacies.

Christie Smith discusses a medically integrated dispensing model that aligns the goals of patients, physicians, and pharmacists.

Rodney E. Rohde, PhD, SM, SV, MB (ASCP), FACSc, leads a discussion on contraindications for vaccination, such as severe allergic reaction history, acute illness with or without fever, and the optimal timing for vaccination during pregnancy.

Panelists compare the currently available RSV vaccines for adults, considering their target populations, dosing, and administration to prevent RSV infection.

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

Tasmina Hydery, PharmD, BCGP, discusses how stakeholders can work together to generate and share real-world evidence on biosimilar effectiveness and switching in order to drive adoption and realize cost savings potential.

Vincent Young, MD, PhD, shares takeaways from Peggy Lillis Foundation's 2024 National C diff Advocacy Summit.

The CEO and co-founder of the Peggy Lillis Foundation discusses highlights from the organization's 2024 National C diff Advocacy Summit.

Shawn Riser Taylor, PharmD, CPP, CDCES, discusses the challenges and process of providing health care in a rural area of Guachipilincito in Honduras.

The use of artificial intelligence and real-time symptom monitoring integrate effectiveness of prescription digital therapeutics for mental health issues

Pharmacists play a key role in psychiatric medication overdose situations

Laura Gillespie, PharmD, discusses some of the financial benefits of having a pharmacist focused on antimicrobial stewardship efforts in a health system.

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.

Experts on the management of ASCVD discuss clinical practice patterns of high-risk patients and the common reasons for clinicians not intensifying cholesterol treatment.

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, highlight the importance of adhering to evidence-based guidelines and utilizing approved medications in the management of hepatic encephalopathy, emphasizing their crucial role in preventing patient relapse within 30 days of hospital discharge.

A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated with maximally tolerated statin monotherapy.

Panelists explore the critical roles of lactulose and rifaximin in managing hepatic encephalopathy, a potentially severe condition that can lead to intensive care unit (ICU) admission.

Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.

Regardless of how this fits into workflow, pharmacists can play a significant role in counseling patients on nutrition and holistic health.

Adrijana Kekic, PharmD, a pharmacogenomics clinical specialist with Mayo Clinic in Phoenix, Arizona, discussed current guidelines for pharmacogenomics.

Pharmacists can play important roles in counseling patients and, in some states, prescribing contraception.

A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.

Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.

Medical experts examine the current treatment landscape and goals for patients with hepatic encephalopathy, addressing patient outcomes and hospital discharge planning, while also acknowledging that some patients may require rehabilitation or long-term care facilities to sustain remission and optimize their recovery.

Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, delve into the complexities of hepatic encephalopathy, exploring the various risk factors that contribute to its development, such as alcohol-induced cirrhosis, sarcopenia, CNS medications, opioids, and other potential triggers.

Sa’ed Al-Olimat, PharmD, co-founder of the Psychedelic Pharmacists Association, discussed the future of psychedelic medicines and the unique ethical challenges they present.

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.